Tag #Global Healthcare

Showing 1 to 5 of 5 results

smh.com.au

🌐 85% Global Worthiness

Jul 10, 10:13

Trump's Pharmaceutical Tariffs Threaten Australia's \$2.2 Billion Export Market

President Trump's suggestion of up to 200 percent tariffs on pharmaceutical imports threatens Australia's \$2.2 billion in pharmaceutical exports to the US, potentially impacting the Pharmaceutical Benefits Scheme (PBS) and leading to higher drug prices for Australians.

Trump's Pharmaceutical Tariffs Threaten Australia's \$2.2 Billion Export Market

President Trump's suggestion of up to 200 percent tariffs on pharmaceutical imports threatens Australia's \$2.2 billion in pharmaceutical exports to the US, potentially impacting the Pharmaceutical Benefits Scheme (PBS) and leading to higher drug prices for Australians.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate economic implications for Australia if the US imposes significant tariffs on pharmaceutical imports?

Australia's pharmaceutical exports to the US were valued at \$2.2 billion in the last year, making it highly vulnerable to potential US tariffs. President Trump's suggestion of tariffs as high as 200 percent, while unlikely to be fully implemented, poses a significant threat. These tariffs could cause substantial economic disruption for Australian pharmaceutical companies.

smh.com.au

🌐 85% Global Worthiness

Mar 13, 10:11

PromarkerD: Predictive Diabetic Kidney Disease Test Launches in Australia

Proteomics International Laboratories launched its PromarkerD predictive test for diabetic kidney disease in Australia on World Kidney Day, initially in Western Australia and the Northern Territory, costing $245 per test and aiming for nationwide rollout and global expansion.

PromarkerD: Predictive Diabetic Kidney Disease Test Launches in Australia

Proteomics International Laboratories launched its PromarkerD predictive test for diabetic kidney disease in Australia on World Kidney Day, initially in Western Australia and the Northern Territory, costing $245 per test and aiming for nationwide rollout and global expansion.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of PromarkerD's launch in Australia on diabetic kidney disease management?

Proteomics International Laboratories launched PromarkerD, a predictive blood test for diabetic kidney disease (DKD), in Australia on World Kidney Day. Initially available in Western Australia and the Northern Territory, it will expand nationwide. The test, costing $245, aims to provide early warning up to four years prior to DKD onset, potentially reducing dialysis and transplant needs.

forbes.com

🌐 85% Global Worthiness

Feb 11, 22:14

Takeda's Plasma-Derived Therapies: Challenges and Growth in a Concentrated Market

Takeda's plasma-derived therapies (PDT) business, generating $5.98 billion in 2023 (21% of total revenue), faces challenges due to concentrated plasma sourcing (90% from 5 countries) and increasing global demand projected to reach $46.7 billion by 2031; Takeda is addressing this through process impr...

Takeda's Plasma-Derived Therapies: Challenges and Growth in a Concentrated Market

Takeda's plasma-derived therapies (PDT) business, generating $5.98 billion in 2023 (21% of total revenue), faces challenges due to concentrated plasma sourcing (90% from 5 countries) and increasing global demand projected to reach $46.7 billion by 2031; Takeda is addressing this through process impr...

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Takeda leveraging technology and data analytics to improve efficiency and yield in its plasma fractionation processes, and what role does patient advocacy play in its strategy?

Takeda collects over 15 million liters of plasma annually, primarily from the U.S. and four European countries, highlighting the industry's geographic concentration and supply chain vulnerabilities. The company is actively diversifying plasma sources and advocating for policy changes to improve global access to these life-saving treatments.

elpais.com

🌐 85% Global Worthiness

May 12, 22:09

Trump Orders Massive US Drug Price Cuts

President Trump signed an executive order mandating a 30-80% reduction in US federal government drug prices within 30 days, leveraging a "most favored nation" policy to match the lowest prices in other developed countries, impacting Medicare and Medicaid.

Trump Orders Massive US Drug Price Cuts

President Trump signed an executive order mandating a 30-80% reduction in US federal government drug prices within 30 days, leveraging a "most favored nation" policy to match the lowest prices in other developed countries, impacting Medicare and Medicaid.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Trump's proposed "most favored nation" policy function, and what are its potential international ramifications?

Trump's order utilizes a "most favored nation" approach, intending to match the lowest price paid by any developed country. This strategy targets pharmaceutical pricing discrepancies between the US and other nations, potentially affecting drug costs for tens of millions of Americans. The stated goal is to save the US government billions of dollars.

cnn.com

🌐 85% Global Worthiness

Feb 26, 07:09

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials

Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials

Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the global significance of Akeso's Ivonescimab outperforming Keytruda in clinical trials?

Akeso, a Chinese biotech firm, developed Ivonescimab, a lung cancer drug that outperformed Merck's Keytruda in clinical trials, extending progression-free survival by 11.1 months versus 5.8 months. This success has significantly boosted Akeso's US partner, Summit Therapeutics, whose stock more than doubled.

Showing 1 to 5 of 5 results